Bone Biologics Corporation
BBLG
$0.55
-$0.01-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.26% | 7.90% | 5.66% | 1.19% | 21.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.02% | -22.47% | -52.85% | -24.78% | -7.61% |
| Operating Income | -8.02% | 22.47% | 52.85% | 24.78% | 7.61% |
| Income Before Tax | -4.48% | 24.69% | 55.01% | 29.15% | 5.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.48% | 24.69% | 55.01% | 29.15% | 5.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.48% | 24.69% | 55.01% | 29.15% | 5.51% |
| EBIT | -8.02% | 22.47% | 52.85% | 24.78% | 7.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 67.57% | 77.74% | 89.68% | 97.39% | 67.00% |
| Normalized Basic EPS | 67.57% | 77.74% | 89.68% | 88.46% | 67.00% |
| EPS Diluted | 67.57% | 77.74% | 89.68% | 97.39% | 67.00% |
| Normalized Diluted EPS | 67.57% | 77.74% | 89.68% | 88.46% | 67.00% |
| Average Basic Shares Outstanding | 222.12% | 238.35% | 335.92% | 514.13% | 186.34% |
| Average Diluted Shares Outstanding | 222.12% | 238.35% | 335.92% | 514.13% | 186.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |